PentaBind
London
About PentaBind
PentaBind, shortlisted by Cancer Research UK as New Startup of the Year, is a cutting edge AI aptamer drug discovery firm that recently saved 38 years of manual drug design time, now awaiting imminent results on the next generation of aptamer drugs that have huge applications in cancer and other diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $959.0K
- Funding stage: Seed
- Last round: Pre-Seed (Jan 2024)
- Website: pentabind.com
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Bioinformatics, Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/pentabind-46445 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.